SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Nuvectis Pharma, Inc. (NVCT) has a negative trailing P/E of -6.6, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 60.2 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -15.15%, forward earnings yield 1.66%. PEG 0.03 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (60/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.03); analyst target implies upside (+14.5%).
- Forward P/E 60.2 — analysts expect a return to profitability with estimated EPS of $0.15 for FY2029.
- PEG Ratio 0.03 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield -15.15% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 1.66% as earnings recover.
- Analyst consensus target $10.00 (+14.5% upside) — modest upside expected.
Overall SharesGrow Score: 44/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
60/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — NVCT
Valuation Multiples
P/E (TTM)-6.6
Forward P/E60.2
PEG Ratio0.03
Forward PEG0.03
P/B Ratio9.48
P/S Ratio0.00
EV/EBITDA-6.5
Per Share Data
EPS (TTM)$-1.21
Forward EPS (Est.)$0.15
Book Value / Share$0.84
Revenue / Share$0.00
FCF / Share$-0.73
Yields & Fair Value
Earnings Yield-15.15%
Forward Earnings Yield1.66%
Dividend Yield0.00%
Analyst Target$10.00 (+14.5%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2020 |
-4,133.3 |
0.00 |
-4,133.28 |
0.00 |
- |
| 2021 |
-3.2 |
0.00 |
-3.75 |
0.00 |
- |
| 2022 |
-5.0 |
-0.13 |
6.68 |
0.00 |
- |
| 2023 |
-5.8 |
1.10 |
10.63 |
0.00 |
- |
| 2024 |
-4.9 |
0.22 |
9.53 |
0.00 |
- |
| 2025 |
-6.2 |
-0.33 |
8.94 |
0.00 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2020 |
$0.00 |
$0.00 |
$-10K |
- |
| 2021 |
$-1.01 |
$0.00 |
$-12.89M |
- |
| 2022 |
$-1.48 |
$149K |
$-18.79M |
-12608.7% |
| 2023 |
$-1.43 |
$0.00 |
$-22.26M |
- |
| 2024 |
$-1.11 |
$0.00 |
$-19M |
- |
| 2025 |
$-1.32 |
$0.00 |
$-26.44M |
- |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-1.27 |
$-1.28 – $-1.25 |
$2.96M |
$2.96M – $2.96M |
4 |
| 2027 |
$-1.32 |
$-1.38 – $-1.25 |
$26M |
$26M – $26M |
4 |
| 2028 |
$-1.16 |
$-2.11 – $1.38 |
$30.73M |
$30.73M – $30.73M |
5 |
| 2029 |
$0.15 |
$0.15 – $0.15 |
$111.06M |
$111.06M – $111.06M |
1 |
| 2030 |
$2.65 |
$2.65 – $2.65 |
$191.64M |
$191.64M – $191.64M |
1 |
